Atıf Formatları
An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

S. Kargun Et Al. , "An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.," Journal of cancer research and therapeutics , no.22, 2024

Kargun, S. Et Al. 2024. An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.. Journal of cancer research and therapeutics , no.22 .

Kargun, S., Aydemir, M., Yilmaz, N., Gürer, İ. E., Sari, R., & Altunbas, H., (2024). An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.. Journal of cancer research and therapeutics , no.22.

Kargun, Sinem Et Al. "An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.," Journal of cancer research and therapeutics , no.22, 2024

Kargun, Sinem Et Al. "An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.." Journal of cancer research and therapeutics , no.22, 2024

Kargun, S. Et Al. (2024) . "An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.." Journal of cancer research and therapeutics , no.22.

@article{article, author={Sinem Kargun Et Al. }, title={An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.}, journal={Journal of cancer research and therapeutics}, year=2024}